Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a singlecenter experience in Korea
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that typically presents in the form of skin manifestations with or without lymph node and bone marrow involvement. Given its rarity and recent recognition as a distinct pathological entity, no standard of treatment exists for this aggressive disease and its prognosis is particularly dismal. Methods: We retrospectively analyzed clinical features and treatment outcomes of patients who were diagnosed with BPDCN between 2000 and 2014. Results: Ten patients had a median age at diagnosis of 41 years (range, 18 to 79), and seven patients were male. Sites of disease involvement were the skin (n = 7), lymph node (n = 5), bone marrow (n = 2), liver (n = 2), spleen (n = 2), and soft tissue (n = 1). Intensified chemotherapy regimens such as hyperCVAD regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), and VPDL (vincristine, methylprednisolone, daunorubicin, L-asparaginase) were used as a first-line treatment. Although all patients treated with intensified chemotherapy showed an objective response (five patients with complete response) with median progression-free survival of 11.2 months (range 6.2 to 19.4), complete remission was not sustained for more than 2 years in any case. The response was relatively long-lived compared with previously reported CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, but the above regimens do not result in long-term remission. Conclusions: All patients treated with hyperCVAD or VPDL showed an objective response, but the duration of response was relatively short. Thus, the development of more effective induction as well as consolidation treatment strategy should be warranted to improve this rare disease entity.
Abstract
Background/Aims: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that typically presents in the form of skin manifestations with or without lymph node and bone marrow involvement. Given its rarity and recent recognition as a distinct pathological entity, no standard of treatment exists for this aggressive disease and its prognosis is particularly dismal. Methods: We retrospectively analyzed clinical features and treatment outcomes of patients who were diagnosed with BPDCN between 2000 and 2014. Results: Ten patients had a median age at diagnosis of 41 years (range, 18 to 79), and seven patients were male. Sites of disease involvement were the skin (n = 7), lymph node (n = 5), bone marrow (n = 2), liver (n = 2), spleen (n = 2), and soft tissue (n = 1). Intensified chemotherapy regimens such as hyperCVAD regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), and VPDL (vincristine, methylprednisolone, daunorubicin, L-asparaginase) were used as a first-line treatment. Although all patients treated with intensified chemotherapy showed an objective response (five patients with complete response) with median progression-free survival of 11.2 months (range 6.2 to 19.4), complete remission was not sustained for more than 2 years in any case. The response was relatively long-lived compared with previously reported CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, but the above regimens do not result in long-term remission. Conclusions: All patients treated with hyperCVAD or VPDL showed an objective response, but the duration of response was relatively short. Thus, the development of more effective induction as well as consolidation treatment strategy should be warranted to improve this rare disease entity.
참고문헌 (23)
- Chaperot L, "Identification of a leukemic counterpart of the plasmacytoid dendritic cells", Blood, 97, pp.3210~3217 (2001)
- Jegalian AG, "Plasmacytoid dendritic cells: physiologic roles and pathologic states", Adv Anat Pathol, 16, pp.392~404 (2009)
- Petrella T, "‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes", Am J Surg Pathol, 26, pp.852~862 (2002)
- Willemze R, "WHO-EORTC classification for cutaneous lymphomas", Blood, 105, pp.3768~3785 (2005)
- Facchetti F, "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", pp.145~147 (2008), IARC Press
- Bueno C, "Incidence and characteristics of CD4(+)", HLA DRhi dendritic cell malignancies, 2004, pp.89, 58~69
- Petrella T, "Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neo-plasms): a review", Am J Clin Pathol, 123, pp.662~675 (2005)
- Riaz W, "Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy", Cancer Control, 21, pp.279~289 (2014)
- Feuillard J, "Clinical and biologic features of CD4(+)CD56(+) malignancies", Blood, 99, pp.1556~1563 (2002)
- Julia F, "Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients", Am J Surg Pathol, 38, pp.673~680 (2014)
- Dalle S, "Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?", Br J Dermatol, 162, pp.74~79 (2010)
- Pagano L, "Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study", Haematologica, 98, pp.239~246 (2013)
- An HJ, "Blastic plasmacytoid dendritic cell neoplasm: a single-center experience", Ann Hematol, 92, pp.351~356 (2013)
- Suzuki R, "Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms", Bone Marrow Transplant, 37, pp.425~431 (2006)
- Aoki T, "Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm", Blood, 125, pp.3559~3562 (2015)
- Lucio P, "CD123hi dendritic cell lymphoma:an unusual case of non-Hodgkin lymphoma", Ann Intern Med, 131, pp.549~550 (1999)
- Vardiman JW, "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes", Blood, 114, pp.937~951 (2009)
- Kharfan-Dabaja MA, "Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation", Biol Blood Marrow Transplant, 19, pp.1006~1012 (2013)
- Petrella T, "Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009?", Autoimmunity, 43, pp.210~214 (2010)
- Reimer P, "What is CD4+CD56+malignancy and how should it be treated?", Bone Marrow Transplant, 32, pp.637~646 (2003)
- Dietrich S, "Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients:results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity", Biol Blood Marrow Transplant, 17, pp.1250~1254 (2011)
- Sanada Y, "Sustained complete remission in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm following autologous peripheral blood stem cell transplantation", Ann Hematol, 92, pp.1285~1286 (2013)
- Lucioni M, "Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion", Blood, 118, pp.4591~4594 (2011)